Cargando…

Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease

Alzheimer’s disease (AD) and Parkinson’s disease (PD) are neurodegenerative diseases (NDD) characterized by progressive degeneration of the central nervous system, and few medications are available to halt the progression of AD and PD. In the present study, an engineered strain MG136-pMG36e-GLP-1 wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fang, Xin, Zhou, Xiaoting, Miao, Yuqing, Han, Yiwen, Wei, Jing, Chen, Tingtao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182653/ https://www.ncbi.nlm.nih.gov/pubmed/32333225 http://dx.doi.org/10.1186/s13568-020-01014-6

Ejemplares similares

Neuroprotective effects of an engineered Escherichia coli Nissle 1917 on Parkinson's disease in mice by delivering GLP‐1 and modulating gut microbiota
por: Wu, Heng, et al.
Publicado: (2022)

Neurotrophic Role of the Next-Generation Probiotic Strain L. lactis MG1363-pMG36e-GLP-1 on Parkinson’s Disease via Inhibiting Ferroptosis
por: Yue, Mengyun, et al.
Publicado: (2022)

Neuroprotective effect of engineered Clostridium butyricum‐pMTL007‐GLP‐1 on Parkinson's disease mice models via promoting mitophagy
por: Wang, Yun, et al.
Publicado: (2023)

Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease
por: Hoekstra, Jake G, et al.
Publicado: (2011)

Engineered Bacteria of MG1363-pMG36e-GLP-1 Attenuated Obesity-Induced by High Fat Diet in Mice
por: Wang, Lingfang, et al.
Publicado: (2021)

GLP-1 and Underlying Beneficial Actions in Alzheimer’s Disease, Hypertension, and NASH
por: Li, Qiu-Xuan, et al.
Publicado: (2021)

Antidiabetic effect of an engineered bacterium Lactobacillus plantarum-pMG36e -GLP-1 in monkey model
por: Luo, Jie, et al.
Publicado: (2021)

Attenuated Postprandial GLP-1 Response in Parkinson’s Disease
por: Manfready, Richard A., et al.
Publicado: (2021)

Neuroprotective Effect of Ceftriaxone on MPTP-Induced Parkinson's Disease Mouse Model by Regulating Inflammation and Intestinal Microbiota
por: Zhou, Xiaoting, et al.
Publicado: (2021)

Role of Vaginal Microbiota Dysbiosis in Gynecological Diseases and the Potential Interventions
por: Han, Yiwen, et al.
Publicado: (2021)

Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics?
por: Tropea, Thomas F., et al.
Publicado: (2021)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
por: Du, Haiyang, et al.
Publicado: (2022)

Engineered Akkermansia muciniphila: A promising agent against diseases (Review)
por: Zou, Yixuan, et al.
Publicado: (2020)

Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice
por: Hedin, Karl Alex, et al.
Publicado: (2023)

Shared Mechanisms of Neurodegeneration in Alzheimer's Disease and Parkinson's Disease
por: Xie, Anmu, et al.
Publicado: (2014)

Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
por: Nowell, Joseph, et al.
Publicado: (2022)

Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment
por: Gejl, Michael, et al.
Publicado: (2017)

The GLP‐1/GIP dual‐receptor agonist DA5‐CH inhibits the NF‐κB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP‐1 single‐receptor agonist NLY01
por: Lv, MiaoJun, et al.
Publicado: (2021)

LncRNAs as the Regulators of Brain Function and Therapeutic Targets for Alzheimer’s Disease
por: Liu, Yuqing, et al.
Publicado: (2022)

GLP-1 and Intestinal Diseases
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

Neuroprotective role of (Val(8))GLP-1-Glu-PAL in an in vitro model of Parkinson's disease
por: Li, Lin, et al.
Publicado: (2016)

Infections among individuals with multiple sclerosis, Alzheimer’s disease and Parkinson’s disease
por: Hu, Yihan, et al.
Publicado: (2023)

Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
por: Zhu, Manlian, et al.
Publicado: (2022)

Microglial autophagy in Alzheimer’s disease and Parkinson’s disease
por: Wang, Zhifu, et al.
Publicado: (2023)

Genetic and environmental factors in Alzheimer’s and Parkinson’s diseases and promising therapeutic intervention via fecal microbiota transplantation
por: Wang, Hui, et al.
Publicado: (2021)

GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease
por: Zheng, Jiaping, et al.
Publicado: (2021)

Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
por: Han, Zhifa, et al.
Publicado: (2018)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Therapeutic Candidates for Alzheimer’s Disease: Saponins
por: Zhang, Ruifeng, et al.
Publicado: (2023)

Emerging small-molecule therapeutic approaches for Alzheimer's disease and Parkinson's disease based on targeting microRNAs
por: Abdelrahman, Somaya A., et al.
Publicado: (2021)

Therapeutic Potential of Heterocyclic Compounds Targeting Mitochondrial Calcium Homeostasis and Signaling in Alzheimer’s Disease and Parkinson’s Disease
por: Tapias, Victor, et al.
Publicado: (2023)

Untangling the Tauopathy for Alzheimer’s disease and parkinsonism
por: Chang, Hui-Yun, et al.
Publicado: (2018)

Genetic networks in Parkinson’s and Alzheimer’s disease
por: Kelly, Jack, et al.
Publicado: (2020)

Alzheimer's and Parkinson's disease therapies in the clinic
por: Chopade, Puja, et al.
Publicado: (2022)

Editorial: Highlights in Alzheimer's and Parkinson's disease
por: Cantone, Mariagiovanna, et al.
Publicado: (2023)

Engineering Neprilysin Activity and Specificity to Create a Novel Therapeutic for Alzheimer’s Disease
por: Webster, Carl I., et al.
Publicado: (2014)

Current Opinion on the Role of Neurogenesis in the Therapeutic Strategies for Alzheimer Disease, Parkinson Disease, and Ischemic Stroke; Considering Neuronal Voiding Function
por: Han, Myung-Hoon, et al.
Publicado: (2016)

Flavonoids as Therapeutic Agents in Alzheimer's and Parkinson's Diseases: A Systematic Review of Preclinical Evidences
por: de Andrade Teles, Roxana Braga, et al.
Publicado: (2018)

Recent Developments in New Therapeutic Agents against Alzheimer and Parkinson Diseases: In-Silico Approaches
por: Cruz-Vicente, Pedro, et al.
Publicado: (2021)

Metabolic Mechanisms Connecting Alzheimer’s and Parkinson’s Diseases: Potential Avenues for Novel Therapeutic Approaches
por: Colca, Jerry R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jq6sa2lrdq2um2n79m4f9r6mqg